

**PA Health & Wellness Pharmacy and Therapeutics Committee Meeting Minutes**  
**1700 Bent Creek Blvd, Suite 200, Mechanicsburg, PA 17050**

**Wednesday, October 09, 2024 – 12:00 PM – 1:30 PM**

**Present:** Jason Skaria, PharmD, Jill Schaeffer, RN, Michelle Bennett, RPh, Dr. Craig Butler, Dr. Christopher Hughes, Dr. Venkateswara Davuluri

**Absent:** Dr. Mahmood Usman Dr. Kolin Good, Grace Robinson (CHC Participant)

**Non-Voting Members:** Amy Nowacki (Pharmacy), Rhonda Montesano (Pharmacy), Shalyn Kline (Pharmacy), Evan Sebastian (Pharmacy), Tanayja Sams (Pharmacy), George Kimbrow (Clinical Policy Coordinator), Heather Clarke (Director of Case Management).

**Call to Order:** The PA Health & Wellness Pharmacy and Therapeutics Committee meeting called to order at 12:02 PM.

**Adjourned:** The PA Health & Wellness Pharmacy and Therapeutics Committee meeting was adjourned at 12:23 PM.

**Next Meeting:** Wednesday, January 08, 2025 – 12:00 PM

**Submitted By:** Shalyn Kline (PHW Pharmacy)

**Committee Chair:** Shalyn Kline, PharmD **Date:** 01/15/2025

**CONFIDENTIAL** Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S.ξ1137 (b)).

Agenda Item	Discussion/Recommendation	Action	Next Steps	Owner
<b>I. Introduction &amp; Call to Order</b>	Jason Skaria called the PA Health & Wellness Pharmacy & Therapeutics Committee meeting to order at 12:02 PM.	Meeting Called to Order		Jason Skaria
A. Introductions	No new introductions			
B. Announcements	<p>Jason reminded all that 75% attendance is required for all voting members to remain as active committee members.</p> <p>Every month, a report is sent to the state. The state provides feedback, and the necessary follow-up is completed.</p>	No action required or taken.		Jason Skaria
C. Explanation of the Review and Approval Process	<ul style="list-style-type: none"> <li>i. Voting and vote totals</li> <li>ii. Tie breaker</li> <li>iii. Pennsylvania’s Review and Approval Process</li> </ul>	No action required or taken.		Jason Skaria
D. Charter Review	The committee charter was reviewed with the committee members.	No action required or taken.		Jason Skaria
<b>II. Approval of Meeting Minutes</b>	<p>A vote was taken for the approval of the minutes from Q3_2024. No objections were made.</p> <p>Motion to approve: Dr. Venkateswara Davuluri Second motion to approve: Jill Schaeffer, RN</p>	Adoption of Q3_2024 Meeting Minutes recorded as approved		Shalyn Kline
<b>III. Old Business</b>	No old business	No action required or taken.		Shalyn Kline

**CONFIDENTIAL** Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §11137 (b)).

A. Policy Submission Status	There are 13 outstanding clinical policies awaiting approval.	No action required or taken.		Shalyn Kline
<b>IV. New Business</b>				
A. Statewide PDL updates	According to the CHC contract, a compliance rate of 95 percent is expected. The compliance rate is currently being audited internally. The Pennsylvania Department of Human Services is conducting an audit of prior authorization determination data.			Jason Skaria
B. Provider Education	A vote was taken for the approval of the HIV provider education. No objections were made.  Motion to approve: Dr. Christopher Hughes Second motion to approve: Dr. Venkateswara Davuluri	The provider education was Committee approved.		Shalyn Kline
C. FDA Updates	This is informational only and addresses recalls, new drugs, etc. No vote necessary.	Informational		Shalyn Kline
D. Guidelines – Drug Coverage Criteria	Review on Combined Summary Table for summary of revisions. A vote was taken for the approval of 14 new policies created, 35 policies had clinically significant change, 44 policies with no significant changes and 4 policies being retired for Medicaid. No objections, concerns or comments were made.  Motion to approve: Dr. Christopher Hughes Second motion to approve: Michelle Bennett	The policy revisions were Committee approved.		Shalyn Kline
E. Additional Drug Lists and Policies and Procedures	A vote was taken for the approval of the Supplemental Drug List, and 2 Pharmacy Policy & Procedures  Motion to approve: Dr. Christopher Hughes Second motion to approve: Dr. Venkateswara Davuluri	The policy and drug lists revisions were Committee approved.		Shalyn Kline

**CONFIDENTIAL** Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

<p>F. Highlights of New Medications/ Significant Changes</p>	<p>Shalyn presented on new drugs to the market: Rezdifra for metabolic dysfunction-associated steatohepatitis (MASH, previously known as NASH) and Kisunla for mild cognitive impairment due to Alzheimer’s. She reviewed there mechanism of action of the 2 new presented drugs.</p> <p>Dr. Hughes asked if we should be covering Kisunla without being in a trial. Shalyn stated our criteria does not require being in a clinical trial for access to this medication. We have not seen a uptake of agents for Alzheimer’s , likely due the possible adverse effects.</p>	<p>No action required or taken.</p>		<p>Shalyn Kline</p>
<p>G. Extra Presentations</p>	<p>Shalyn presented on Glucose-like Peptide-1 (GLP-1) Agonists per a P&amp;T member request. She presented on the indications and the preferred agents for CHC members. She also went over the review process for Dual members.</p> <p>Shalyn presented the statewide PDL policies that may have changes for 2025. She provided the link to submit comments in the invite on October 4, as the deadline to submit comments was October 7.</p>	<p>No action required or taken.</p>		<p>Shalyn Kline</p>
<p>H. Complaints and Grievances Review</p>	<p>Shalyn stated that there was 1 determinations upheld and 4 overturned and 0 withdrawn during pre-grievance. Zero of the 5 determinations were for opioids. Two determinations were for GLP-1 Receptor Agonists</p>	<p>No action required or taken.</p>		<p>Shalyn Kline</p>
<p>I. Drug Utilization Review</p>	<p>Evan presented the drug utilization review, noted the numbers are for July-September and involve several outreach categories (Adherence, Drug-Drug Interactions, Duplicative Therapy, Excessive Use, High-Risk Medication, Inappropriate Dose, Inappropriate Duration of Therapy, Lack of Therapy)</p> <p>A total of 6482 DUR outreaches were made and 320 resolutions (4.9% resolved).</p> <p>FWA – There were 93 Participants reviewed with 90 Morphine Milligram Equivalent (MME) or more. 14 participants were identified for prescriber outreach. Ten participants were identified</p>	<p>No action required or taken.</p>		<p>Evan Sebastian</p>

**CONFIDENTIAL** Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S.1137 (b)).

	with three or more practices/hospitals prescribing opioids and are under further review.			
J. PBM Oversight	<p>Prior Authorization Audits:</p> <ul style="list-style-type: none"> <li>July – 94.44% passed</li> <li>August – 93.51% passed</li> <li>September – 91.11% passed</li> </ul> <p>Call Center:</p> <ul style="list-style-type: none"> <li>July – 597 calls – 98.16% within TAT</li> <li>August – 666 calls – 97.51% within TAT</li> </ul> <p>Jason stated there is a remediation plan in place to curve the downward trend on Prior Authorizations passing. Dr. Hughes asked what is involved in the remediation plan. Jason stated there are new reviewers and Centene Pharmacy Services is educating and working with the reviewers.</p>	No action required or taken.		Jason Skaria
K. Open Forum		No action required or taken.		Shalyn Kline
Adjournment	<p>The meeting was adjourned at 12:23pm</p> <p>Jason asked for a motion to adjourn.  Motion to adjourn: Dr. Christopher Hughes  Second motion to adjourn: Jill Schaeffer, RN</p>	Meeting adjourned		Jason Skaria

**CONFIDENTIAL**

Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

